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Menin as a hub controlling mixed
lineage leukemia
Austin T. Thiel1), Jing Huang2)3), Ming Lei2)3) and Xianxin Hua1)
Mixed lineage leukemia (MLL) fusion protein (FP)-
induced acute leukemia is highly aggressive and often
refractory to therapy. Recent progress in the field has
unraveled novel mechanisms and targets to combat this
disease. Menin, a nuclear protein, interacts with wild-
type (WT) MLL, MLL-FPs, and other partners such as the
chromatin-associated protein LEDGF and the transcrip-
tion factor C-Myb to promote leukemogenesis. The
newly solved co-crystal structure illustrating the menin–
MLL interaction, coupled with the role of menin in
recruiting both WT MLL and MLL-FPs to target genes,
highlights menin as a scaffold protein and a central hub
controlling this type of leukemia. The menin/WT MLL/
MLL-FP hub may also cooperate with several signaling
pathways, including Wnt, GSK3, and bromodomain-
containing Brd4-related pathways to sustain MLL-FP-
induced leukemogenesis, revealing new therapeutic
targets to improve the treatment of MLL-FP leukemias.
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Introduction
Chromosomal translocations involving the mixed lineage leu-
kemia (MLL) gene occur with one of multiple partner genes,
leading to the formation and expression of MLL fusion
proteins (MLL-FPs) and the development of acute leukemias
[1]. These acute leukemias can be lymphoid (ALL), myeloid
(AML), or biphenotypic in nature [2]. MLL translocations are
found in 10% of all leukemias and the majority of infant
leukemia cases, and patients harboring this genetic abnor-
mality have a particularly poor prognosis [3, 4].
The wild-type (WT) MLL protein is post-translationally
cleaved by the protease taspase-1 into N-terminal (MLL-N) and
C-terminal (MLL-C) fragments, which then re-associate to form
the MLL complex [5]. WT MLL is recruited via MLL-N to target
genes through interactions with various proteins, including
menin, LEDGF, and C-Myb, as well as its CxxC domain, leading
to transcriptional activation of these targets (Fig. 1A) [6–9]. Target
gene activation is mediated, at least in part, through histone H3
lysine 4 trimethylation (H3K4m3) catalyzed by the MLL C-terminal
SET domain, in concert with the cofactors Wdr5, Ash2L, and
Rbbp5 (Fig. 1A) [10–12]. Direct WT MLL targets include HOX
genes, which are activated in a controlled manner during normal
hematopoiesis, with high expression in progenitor cells, but
decreased expression during cell differentiation [13, 14].
MLL-FPs retain a portion of MLL-N, including domains
important for its recruitment to MLL target genes, but
lack a large C-terminal portion of the protein, including the
H3K4-methylating SET domain (Fig. 1B,C). Although MLL-C is
lacking in MLL-FPs, MLL-FP expression still leads to the upre-
gulation of HOX genes [15, 16], which restrain progenitor cells
from differentiation and cause leukemia when overexpressed
in mouse bone marrow (BM) [17]. These findings appear to
suggest that leukemogenesis does not require the C-terminal
portion of MLL (Fig. 1B,C).
However, one allele of WT MLL remains intact in MLL-FP-
expressing leukemia cells. Recent work has demonstrated a
critical role for the remaining WT allele of MLL in MLL-AF9-
mediated leukemogenesis [8, 18]. The biochemical mechanisms
by which MLL-FPs affect chromatin modification and transcrip-
tional elongation have been extensively reviewed [19–23]. This
review focuses on the roles of, and interplay between, menin,
WT MLL, and MLL-FPs in gene transcription and leukemic
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transformation in MLL-FP-mediated leukemia, as well as their
potential interplay with other proteins and signaling pathways.
Recent findings highlight menin as a central component regu-
lating MLL-FP-mediated leukemia, and a potential target for the
pharmacological inhibition of MLL-FP leukemias.
MLL fusion proteins promote HOX gene
expression and leukemogenesis
The driving force behind MLL-FP leukemia is the fusion
protein itself, as its expression causes HOX gene upregulation
and leukemic transformation [16, 24, 25]. Leukemogenesis is
achieved even though a large C-terminal portion of WT MLL,
which is normally required for the activation of HOX gene
transcription, is lost due to the chromosomal translocation.
Some less frequently occurring MLL-FPs have cytosolic fusion
partners, such as AF6, GAS7, EEN, and septin proteins, and
MLL-GAS7 does not require Hoxa9 for BM transformation
[20, 26]. However, the most common MLL-FPs have nuclear
fusion partners, and these MLL-FPs upregulate HOX genes to
promote leukemogenesis [20]. It was initially puzzling how
these MLL-FPs activated HOX genes to an even greater extent
than WT MLL. Several important studies have since led to a
greater understanding of the mechanism of MLL-FP-mediated
HOX gene upregulation and leukemogenesis.
Dot1L interacts with MLL-FPs, and is required for
MLL-FP-mediated transformation
Many MLL-FPs recruit the histone H3 lysine 79 (H3K79) meth-
yltransferase Dot1L to target genes, promoting leukemogene-
sis. MLL translocation partners, including AF9, ENL, and
AF10, exist in a complex with Dot1L, and MLL-FPs containing
these fusion partners retain the ability to interact with
Dot1L, leading to increased H3K79 methylation at target genes
[27, 28]. Although it is not yet known how H3K79 methylation
regulates transcription, it is frequently found at active genes
[29].
Enhanced transcription of MLL targets is associated with
MLL-FP recruitment of Dot1L to these genes. Hox gene upre-
gulation and leukemic transformation is contingent upon the
interaction between MLL-AF10 and Dot1L [30, 31].
Additionally, direct fusion of Dot1L to MLL-N transforms
mouse BM, while a Dot1L catalytic mutant fused to MLL-N
fails to do so [30]. These findings suggest that Dot1L catalytic
activity is necessary for MLL-FP-mediated leukemogenesis.
Also, MLL-FP-mediated BM transformation is suppressed by
deletion or catalytic inhibition of Dot1L [32–36]. These obser-
vations support a model whereby MLL-FPs recruit Dot1L to
target genes, leading to enhanced H3K79 methylation, upre-
gulation of these genes, and leukemogenesis (Fig. 1B).
However, it is unclear how H3K79m2 might promote HOX
gene expression, and an MLL-Dot1L fusion that retains its
catalytic activity, but cannot recruit pTEFb (see below) to
target genes, is unable to transform mouse BM [37], suggesting
that recruitment of Dot1L catalytic activity alone is insufficient
for leukemic transformation. In addition, MLL-AF4, which
interacts with pTEFb but not Dot1L, causes leukemia [37],
suggesting that direct Dot1L recruitment is not absolutely
required for leukemogenesis mediated by at least some
MLL-FPs. Even so, H3K79 methylation is still enriched
at MLL targets in MLL-AF4 cells [38], and Dot1L catalytic
inhibition is effective in reducing Hox gene expression and
Figure 1. Menin/WT MLL and menin/MLL-FP
complexes, and chromatin modifications cata-
lyzed by these complexes. A: The MLL-C SET
domain catalyzes H3K4m3. The MLL-C TAD
interacts with the histone acetyltransferases
CBP and MOF. B: Many MLL-FPs interact with
and recruit the H3K79 methyltransferase Dot1L
to MLL target genes. Dot1L can be inhibited by
EPZ004777. C: Many MLL-FPs also recruit the
pTEFb (cyclin T/CDK9) kinase complex to MLL
target genes, leading to dysregulated transcrip-
tional elongation. pTEFb can be inhibited with
the drugs austerpaullone and flavopiridol. The
indirect interaction of menin with other partners
such as Dot1L or pTEFb is hypothetical based
on deduction. The size of proteins is not drawn
to scale.
A. T. Thiel et al. Prospects & Overviews....
772 Bioessays 34: 771–780, 2012 WILEY Periodicals, Inc.
R
e
v
ie
w
e
s
s
a
y
s
viability in these cells [36]. Future work may provide a clearer
understanding as to how Dot1L regulates transcription and its
precise role in MLL-FP leukemic transformation.
PTEFb interacts with MLL-FPs, and promotes HOX gene
transcription and leukemogenesis
MLL-FP recruitment of the pTEFb complex to target genes
promotes transcriptional elongation, providing another mech-
anism for transformation by MLL-FPs. Some of the same MLL
fusion partners that interact with Dot1L, such as AF9 and ENL,
as well as other fusion partners including AF4, are part of a
distinct complex containing pTEFb – a kinase consisting of the
cyclin T and CDK9 proteins that promotes transcriptional
elongation [27, 39, 40]. Transcriptional elongation is regulated
at many developmentally relevant genes that have an initiated
or ‘‘poised’’ RNA polymerase II (Pol II) resting at their pro-
moters [41]. Initiated Pol II is phosphorylated by pTEFb at
serine 2 of its C-terminal domain (CTD), causing Pol II to be
released from the promoter and allowing transcriptional
elongation [42].
The expression of MLL-FPs, including MLL-AF9, -ENL, and
-AF4, leads to pTEFb recruitment to MLL target genes and
enhanced transcriptional elongation (Fig. 1C) [37, 43]. MLL-FP
leukemia cell lines are more sensitive to the CDK9 inhibitors
flavopiridol and alsterpaullone than non-MLL-FP cell lines,
suggesting that dysregulated transcriptional elongation at
MLL targets is at least one mechanism for leukemic transform-
ation by MLL-FPs (Fig. 1C) [43]. The finding that MLL-FPs
recruit Dot1L and/or pTEFb to target genes, leading to their
upregulation, has provided an insight into the mechanism of
MLL-FP-mediated leukemogenesis.
Wild-type MLL is required for MLL-FP-
mediated HOX gene upregulation and
leukemogenesis
In addition to the MLL-FP, expression of non-translocated WT
MLL is required to maintain the transformed state of MLL-FP
leukemia cells, likely through C-terminal domains that are
lacking in the fusion protein. While MLL-FP cells have one
translocated allele, which results in the expression of MLL-
FPs, the other allele of MLL remains intact and expresses full-
length WT MLL. WT MLL is not only expressed, but binds
target genes in MLL-FP cell lines [18, 44]. MLL-FPs lack a large
C-terminal portion of WT MLL that is normally necessary
for target gene activation. However, MLL-C function is still
carried out in MLL-FP cells by expression of WT MLL from the
non-translocated allele.
Non-translocated WT MLL is critical for maintaining the
transformed state of MLL-FP leukemias, and the survival of
MLL-AF9 mice is prolonged by WT MLL knockout [18]. WT MLL
depletion in human MLL-AF9 cells not only leads to a decrease
in HOX gene transcription and WT MLL-mediated H3K4m3,
but also reduces MLL-AF9-induced H3K79m2, indicating that
MLL-FP function requires WT MLL [18]. WT MLL is necessary
for MLL-AF9 recruitment to Hox genes in MEFs, but there is no
physical interaction between MLL-AF9 and WT MLL [8].
Therefore, WT MLL function may indirectly lead to MLL-FP
recruitment through chromatin modifications mediated by
C-terminal domains that are lacking in MLL-FPs, such as
the trans-activation domain (TAD) and SET domain (Fig. 1A).
The potential role of WT MLL-mediated H3K4m3 in
MLL-FP leukemias
MLL-C SET domain-catalyzed H3K4m3 is associated with tran-
scriptional activation, and may be important for the activation
of WT MLL/MLL-FP target genes through the recruitment of
certain proteins that specifically bind this chromatin modifi-
cation. Mice expressing MLL lacking the SET domain are
viable, but exhibit skeletal defects and decreased Hox expres-
sion, suggesting that the SET domain and H3K4m3 are
required for optimal expression of MLL target genes during
development [12].
H3K4m3 is specifically recognized by various ‘‘reader’’
proteins. One of these readers is WT MLL itself, which recog-
nizes H3K4m3 via its third PHD (PHD3) domain at target gene
promoters (Fig. 2A) [45, 46]. The H3K4m3 mark is recognized
by PHD3 through a hydrophobic cavity, ‘‘reading’’ the gene as
active, and retaining the active chromatin state [45]. It is likely
that the recognition of H3K4m3 by PHD3 allows the propa-
gation of active histone modifications catalyzed by WT MLL
and its interacting partners, maintaining the chromatin in a
conformation conducive to MLL-FP binding. MLL-FPs invar-
iably lack the WT MLL PHD domains. Interestingly, overex-
pression of MLL-ENL containing the PHD3 domain fails to
transform mouse BM [47]. However, it is not yet understood
why MLL-FPs must contain MLL-N lacking the PHD domains.
Another reader of H3K4m3 is BPTF, a subunit of the NuRF
chromatin-remodeling complex. BPTF specifically binds
nucleosomes that contain both H3K4m3 and acetylated
histone H4 at lysine 16 (H4K16Ac) via adjacent PHD- and
bromo-domains (Fig. 2B) [48–50]. BPTF has also been found
to bind Hox loci [49]. Hox gene expression is altered by BPTF
knockdown in Xenopus during development, but it is not yet
known whether BPTF regulates HOX gene expression in MLL-
FP leukemia cells [48].
In MLL-AF9 leukemia cells, the chromodomain-containing
protein CHD1 also recognizes H3K4m3, and localizes to Hox
genes, but has not yet been implicated in MLL-FP-mediated
leukemogenesis (Fig. 2C) [9, 51]. Future studies will determine
whether WT MLL complex-catalyzed H3K4m3 and the reading
of this mark by CHD1 and BPTF are involved in restructuring
chromatin to allow MLL-FP binding and HOX gene upregula-
tion (Fig. 2B,C).
The potential role of the WT MLL TAD and histone
acetylation in MLL-FP leukemias
In addition to the SET domain, the WT MLL TAD, which
promotes histone acetylation, a feature of actively transcribed
genes, may have a role in the activation of MLL target genes in
MLL-FP cells. WT MLL interacts with the histone acetyltrans-
ferase (HAT) enzymes MOF and CREB binding protein (CBP;
Fig. 1A) [52, 53]. CBP directly interacts with the WT MLL TAD,
and CBP is required for MLL transactivation activity in normal
cells [52]. An MLL-CBP fusion aberrantly recruits CBP to MLL
targets, causing myeloproliferative disease, supporting a
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potential role for CBP in MLL-FP pathogenesis [54]. The WT
MLL TAD also interacts with MOF, an H4K16 acetyltransferase
[53].
The dual bromodomain-containing protein Brd4 recog-
nizes acetylated histones [55]. However, it is not known
whether Brd4 recognizes histone acetylation mediated by
WT MLL at target genes. Nonetheless, Brd4 may have a role
in MLL-FP recruitment to target genes. Brd4 recruits PAFc and
pTEFb to gene loci [56, 57], and PAFc/pTEFb interact with
MLL-FPs [37, 58], providing a link between MLL-FPs and
chromatin (Fig. 2D). In support of this model, Brd4 inhibition
causes a decrease in PAFc, pTEFb, and PolII CTD phospho-S2
at the promoter of Bcl-2, a direct MLL-FP target gene [57].
Also, BPTF recognizes H3K4m3 and H4K16Ac simul-
taneously, suggesting that the TAD may act in concert with
the SET domain to maintain chromatin in a conformation
conducive to MLL-FP binding [48, 49]. Future studies will
determine whether WT MLL SET domain-catalyzed H3K4m3
and/or WT MLL TAD-mediated histone acetylation are
involved in MLL-FP-mediated leukemogenesis.
WT MLL and MLL-FPs share N-terminal
domains critical for their recruitment to
target genes
Although the C-terminal portions of WT MLL and MLL-FPs
possess quite distinct activities, the N-terminal regions of
these proteins, which are responsible for recruitment to target
genes, are mostly shared and function in a similar manner
with only subtle differences (Fig. 1).
Menin captures the N-terminus of MLL through a deep
pocket
The interaction between MLL-N and menin is pivotal to
the physiological, as well as the pathological, roles of
MLL [9, 59–61]. MLL-dependent transcription and MLL-FP-
mediated leukemic transformation also require the LEDGF
protein, which interacts with MLL-N and menin [6].
Recently, crystallographic studies of the structures of menin
in its free form and in complex with MLL or an MLL-LEDGF
heterodimer explain how menin acts as a central ‘‘hub’’
through its role in recruiting both WT MLL and MLL-FPs to
target genes [62, 63].
Menin interacts with a bipartite motif at the extreme N-
terminus of MLL consisting only of residues 6–25 (MLL1MBM:
menin-binding motif), a region that is found in both WT MLL
and MLL-FPs. The crystal structures of menin alone and in
complex with the MLLMBM peptide reveal that menin adopts a
rectangular-shaped conformation, resembling a curved left
hand, with a deep pocket formed by its thumb and palm
domains (Fig. 3A,B). The thumb domain of menin is structur-
ally similar to the transglutaminase-like fold of the transglu-
taminase superfamily, and the palm domain contains three
TPR motifs that usually serve as protein–protein interaction
modules. The MLLMBM peptide adopts a highly coiled confor-
mation and plugs into the deep pocket of menin. The inter-
action affinity and specificity between menin and MLLMBM is
mainly determined by extensive hydrophobic contacts at the
bottom of the deep pocket of menin (Fig. 3C). Disruption of the
interaction between menin and MLL-N diminishes WT MLL-
mediated H3K4m3 and MLL-AF9 enrichment at the Hoxa9
promoter and decreases Hoxa9 expression in transformed
mouse BM, highlighting the importance of the menin–MLL-
N interaction for MLL-FP-mediated leukemogenesis (Fig. 4)
[60].
Menin serves as a scaffold protein to assemble a menin–
MLL–LEDGF ternary complex
Menin/WT MLL and menin/MLL-FP complexes are guided to
MLL target genes through additional interactions with the
chromatin-associated LEDGF protein. [6, 62]. Notably,
LEDGF binds to menin/MLL-N with high affinity, whereas
neither menin nor MLL-N alone stably associate with
Figure 2. Readers of epigenetic modifications
mediated by menin/WT MLL. A: The WT MLL
PHD domain specifically associates with
H3K4m3. B: BPTF (part of the NuRF complex)
binds H3K4m3 and H4K16Ac via its tandem
PHD- and bromo-domains. C: CHD1 specifi-
cally recognizes H3K4m3. D: Brd3/4 bromodo-
main-containing proteins interact with
acetylated histone and may recruit MLL-FPs to
target genes through PAF/pTEFb interactions.
The Brd protein inhibitors JQ1 and I-BET151
cause MLL-FP leukemia cell death.
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LEDGF. The crystal structure of the menin/MLL-N/LEDGF
complex also indicates that the integrase-binding domain of
LEDGF (LEDGFIBD) binds to a V-shaped groove formed by both
menin and MLL-N (Fig. 3D). Menin acting as a scaffold protein
to mediate the MLL-N/LEDGF interaction underscores the
central role of menin in MLL-FP leukemias (Fig. 4).
C-Myb interacts with menin and is critical for
MLL-FP-mediated transformation
In MLL-FP leukemia cells, menin also interacts with the C-Myb
transcription factor, which is essential for WT MLL, and pre-
sumably, MLL-FP recruitment to target genes (Fig. 1) [7]. C-
Myb is required for optimal HOX gene expression in human
MLL-FP leukemia cell lines, and MLL-ENL-mediated trans-
formation is suppressed by expression of a C-Myb fragment
that binds DNA, but lacks the menin-interaction domain [7].
The role of the menin/C-Myb interaction in MLL-FP leukemias
again highlights menin as a central player in this disease
(Fig. 4).
The CxxC domain is critical for WT MLL and MLL-FP
recruitment to target genes
Another common feature of WT MLL and MLL-FPs is the CxxC
domain, which interacts with the PAFc complex and is
required for WT MLL and MLL-FP binding to Hox genes
(Fig. 1) [8, 58]. The CxxC domain also interacts with unmethy-
lated CpG DNA sites [64–66]. Interestingly, disruption of
the CxxC-DNA interaction with a point mutation (K1176A)
abrogates MLL-AF9, but not WT MLL binding to the Hoxa9
promoter [64]. This discrepancy could be due to the fact that
MLL-FPs lack PHD3, which may stabilize WT MLL at target
genes, further suggesting that an ‘‘open’’ chromatin confor-
mation is critical for MLL-FP binding and stabilization at such
target genes.
However, the necessity of the CxxC-DNA interaction for
MLL-AF9 recruitment is still unclear, as another point
mutation abrogating CxxC DNA binding (C1188D) has no effect
on MLL-AF9 binding in MEFs, but is still required for MLL-AF9-
mediated leukemogenesis, potentially by affecting methyl-
ation of CpG islands at the Hoxa9 promoter [66]. As WT
MLL and MLL-FP recruitment are controlled by the same
interacting proteins, which are largely coordinated by menin,
menin may be particularly important for regulating two dis-
tinct functions controlling HOX gene upregulation and leuke-
mogenesis (Fig. 4).
Direct transcriptional targets of menin/WT
MLL/MLL-FPs
MLL-FP recruitment to HOX genes and other recently ident-
ified target genes causes enhanced transcriptional elongation
and subsequent overexpression of these genes. These direct
MLL-FP targets play various roles in promoting leukemic dis-
ease, highlighting the importance of investigating genes that
are upregulated by MLL-FPs. Understanding MLL-FP down-
stream effectors has yielded further insight into the mechan-
ism by which expression of these fusion proteins causes
leukemia.
Figure 3. Structural insights into the menin/MLL interaction.
A: Domain organization of menin, MLL, and LEDGF. Interactions
among the three proteins are denoted. B: Overall structure of the
menin-MLLMBM complex. C: Detailed view of the menin-MLLMBM
interface. D: Ribbon diagram of the menin/MLL/LEDGF complex.
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HOX genes are critical downstream effectors of MLL-FP-
mediated leukemogenesis
In MLL-FP leukemias, HOX genes have been implicated in
promoting cell survival and blocking differentiation to
promote leukemogenesis. In mammalian cells, there are 39
Hox genes residing in four distinct clusters on four respective
chromosomes [67]. In particular, HOXA9 and its dimerization
partner MEIS1 are the most well characterized direct targets
of the MLL-FP pathway. MLL-AF9 leukemic disease can be
mimicked by overexpression of HOXA9 and MEIS1 [16, 17].
Also, Hoxa9/Meis1 overexpression is able to rescue BM
colony formation defects caused by menin or WT MLL
depletion, demonstrating that Hox genes are critical down-
stream mediators of MLL-FP-mediated leukemia [9, 18]. In
addition, shRNA-mediated depletion of HOXA9 in human
MLL-AF9 cells causes growth arrest, increased expression of
differentiation-associated genes, and apoptosis, indicating
various roles for HOX genes in leukemogenesis [68]. As
HOX genes themselves are transcription factors, it is likely
that MLL-FP-mediated HOX gene upregulation leads to
increased transcription of multiple HOX target genes involved
in leukemogenesis. Further investigation into the direct down-
stream targets of HOXA9/MEIS1 will yield more insight into the
yet uncharacterized mechanisms by which these genes func-
tion to regulate critical processes in MLL-FP leukemia cells.
MLL-FPs directly activate additional genes that have a
role in leukemogenesis
Recently, global approaches have led to the discovery of
previously unrecognized direct MLL-FP target genes that
promote MLL-FP-mediated transformation. A comparison of
MLL-FP-expressing cells with cells containing only WT MLL
has demonstrated that MLL-FPs regulate a subset (15%) of
WT MLL target genes [44]. Two of these genes, Six1 and Eya1,
are able to transform mouse BM, demonstrating a role for these
proteins in leukemogenesis [44]. Additionally, Evi1, a gene
that was discovered as a common retroviral integration site in
murine leukemias, was found to be a direct MLL-AF9 target
in mouse hematopoietic stem cells (HSCs) [69]. Future exper-
iments may lead to the discovery of more direct MLL-FP targets
involved in leukemogenesis.
Signaling pathways regulating MLL-FP
leukemias
In addition to direct downstream targets of MLL-FPs, which
are critical for leukemic transformation, signaling pathways
have been found that cooperate with MLL-FP function to
regulate leukemogenesis. These pathways include GSK-3 sig-
naling, which modulates Hoxa9/Meis1 function, Wnt signal-
ing, and the Akt/Foxo pathway. Understanding pathways that
function in concert with, or in parallel to, MLL-FPs has led
to a broader understanding of the cellular context in which
MLL-FPs function.
GSK-3 regulates HOX function downstream of MLL-FPs
The GSK-3 serine/threonine kinase promotes MLL-FP-medi-
ated leukemogenesis by increasing the recruitment of
HOXA9 and its cofactor MEIS1 to target genes. GSK3 has a
role in multiple cellular pathways, such as Wnt signaling. Wnt
signaling is repressed by GSK-3, which induces b-catenin
phosphorylation and degradation [70, 71]. Interestingly, inde-
pendent of its role in Wnt signaling, GSK-3 has an opposing
pro-oncogenic role in MLL-FP leukemia, as its inhibition leads
to G1 arrest [72]. Further investigation into how the cell cycle is
regulated by GSK-3 demonstrated its ability to directly phos-
Figure 4. Menin as a central hub regulating WT
MLL and MLL-FPs. Menin binds the N-terminus
of either WT MLL or MLL-FPs, together with
C-Myb and LEDGF (middle). The interaction
between menin and LEDGF requires MLL-N.
The PAF complex interacts with the CxxC
domain of both WT MLL and MLL-FPs. The
proteins interacting with the C-terminal part of
WT MLL or MLL-FPs are distinct (top and bot-
tom). WT MLL and MLL-FPs are recruited to
many of the same target genes.
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phorylate CREB, leading to the formation of a complex includ-
ing CREB, MEIS1, HOXA9, and CBP that activates HOX/MEIS1
downstream targets (Fig. 5A) [73]. These results identify GSK-3-
mediated HOX protein recruitment as a critical pathway for
MLL-FP-mediated leukemogenesis.
Wnt signaling is required for MLL-FP-mediated
leukemogenesis
The Wnt pathway is also crucial for MLL-FP-mediated leuke-
mogenesis, as b-catenin knockout impairs the ability of MLL-
AF9-expressing cells to cause leukemia (Fig. 5C) [74, 75].
Although Wnt signaling is essential for MLL-FP leukemia,
inhibition of GSK-3, which activates Wnt signaling, leads to
MLL-FP cell death by inhibiting binding of HOXA9/MEIS1 to
target genes (Fig. 5B) [72, 73]. These results suggest that in the
absence of HOXA9/MEIS1 function, Wnt signaling is unable to
sustain MLL-FP-mediated leukemogenesis.
MLL-FPs may independently regulate Wnt signaling
through their interaction with Dot1L. The native Dot1L com-
plex, in addition to MLL fusion partners, also contains
the Wnt pathway components TRRAP, Skp1, and b-catenin
in 293T cells [28]. This finding suggests that MLL-FPs
regulate Wnt signaling at least in part through their inter-
action with Dot1L in MLL-FP leukemia cells, possibly
through stabilizing or aiding in the recruitment of the
Dot1L complex to Wnt targets. Although it is unclear whether
Dot1L regulates Wnt signaling in MLL-FP cells, Wnt signaling
is upregulated by MLL-FPs and is essential for MLL-FP
leukemia.
Low Akt signaling, resulting in Foxo activation, is
required for MLL-FP leukemia stem cells
Akt activity is low in MLL-AF9 leukemia stem cells (LSCs), and
overexpression of a constitutively active form of Akt leads to
MLL-AF9 cell differentiation [76]. In MLL-FP leukemias, low
Akt signaling leads to nuclear translocation and activation of
Foxo proteins. Depletion of Foxo1/3/4 increases the survival
rate of mice transplanted with MLL-AF9-transduced primary
BM cells, demonstrating a pro-oncogenic role for Foxo genes in
MLL-AF9 leukemia, in part through activation of the JNK/Jun
pathway [76]. In addition to GSK-3, Wnt, and Akt/Foxo, it is
likely that yet unidentified signaling pathways are involved in
MLL-FP-mediated leukemogenesis.
Potential therapeutic targets of
the menin-WT MLL-MLL-FP pathway
Substantial progress has been made in understanding the
mechanism of MLL-FP-mediated leukemogenesis and the
critical signaling pathways in these cells. Pharmacological
inhibition of these targets may be effective in treating patients
with this disease.
Inhibition ofWnt signaling as a potential therapy forMLL-
FP leukemias
Inhibition of Wnt signaling by b-catenin knockout depletes
MLL-FP LSCs and increases the survival of MLL-FP leukemic
Figure 5. A model for the role of GSK-3 and Wnt
signaling in MLL leukemia. A: In MLL-FP leukemia
cells, GSK-3 signaling is active, leading to CREB
phosphorylation and recruitment of Hox proteins to
target genes. Although GSK-3 is active, Wnt signaling
occurs at a basal level. B: GSK-3 inhibition
suppresses the binding of Hox proteins to target
genes, but also activates Wnt signaling. Even in the
presence of activated Wnt signaling, leukemia cells
are suppressed. C: Deletion or inhibition of b-catenin
with indomethacin in MLL-FP cells also leads to
leukemia suppression, demonstrating a critical role for
Wnt signaling in MLL leukemia.
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mice, highlighting the Wnt pathway as a potential target for
treating this disease [74, 75]. Importantly, Wnt signaling does
not affect adult HSCs in mice [77], decreasing the likelihood of
toxicity due to Wnt inhibition. The Wnt pathway inhibitor
indomethacin, a commonly used anti-inflammatory drug,
inhibits Cox1/Cox2 and causes b-catenin degradation in
MLL-FP cells [75, 78]. Treatment of MLL-AF9 leukemic mice
with indomethacin leads to a modest yet significant increase in
survival time, suggesting that MLL-FP leukemia can be sup-
pressed by pharmacological inhibition of the Wnt pathway
(Fig. 5C) [75].
Since Wnt pathway components are found in a complex
with Dot1L [28], it is possible that Dot1L inhibition could
decrease not only HOX gene expression, but also Wnt
signaling. It should be noted, however, that inhibition of
Wnt signaling is less effective in later stages of the disease
[75], suggesting that a Wnt inhibitor may only be useful
in combination with other therapies to effectively treat this
disease.
Inhibition of GSK-3 as a potential therapy for MLL-FP
leukemias
GSK-3, through phosphorylation of CREB, leads to MEIS1
recruitment to target genes [73]. Since HOXA9/MEIS1 are
critical mediators of MLL-FP-mediated leukemogenesis, inhi-
bition of GSK-3 could be a viable treatment option for this
type of leukemia. In support of this theory, GSK-3 inhibition
with lithium chloride, a common treatment for bipolar dis-
order, prolongs the survival of MLL-AF4 leukemic mice
(Fig. 5B) [73].
Although GSK-3 inhibition is initially effective, mice even-
tually become resistant to therapy and succumb to disease
[73]. One possible mechanism for resistance is that, in addition
to inhibiting HOXA9/MEIS1 targets with GSK-3 inhibition,
inhibiting GSK-3 also activates the Wnt pathway, which is
essential for MLL-FP leukemia (Fig. 5B). MLL-FP cells are
re-sensitized to GSK-3 inhibition by Wnt pathway disruption
through depletion of b-catenin, suggesting that a combination
of GSK-3 and Wnt inhibition may increase treatment efficacy
[74].
Directly targeting MLL-FP function to treat MLL-FP
leukemias
As MLL-FPs are the driving force behind leukemogenesis, it
seems logical to directly target fusion protein function
through inhibition of Dot1L or pTEFb. Along these lines,
mice xenografted with MLL-AF4 leukemia cells have a
modest but significant increase in survival when treated
with EPZ004777, a Dot1L catalytic inhibitor, underscoring
the potential for targeting Dot1L to treat MLL-FP leukemia
(Fig. 1B) [36].
Also, pTEFb inhibition with the CDK9 inhibitors flavopir-
idol or alsterpaullone shows some selectivity towards MLL-FP
cell lines (Fig. 1C) [43], and clinical trials involving flavopiridol
and other CDK9 inhibitors are ongoing for the treatment of
chronic lymphocytic leukemia and acute leukemias, present-
ing a possible avenue for MLL-FP leukemia therapy in the
future [79, 80].
The use of BET bromodomain inhibitors to
treat MLL-FP-induced leukemia
The potential for treating MLL-FP leukemia patients by block-
ing Brd4 binding to acetylated histone through chemical inhi-
bition is promising. Two specific inhibitors that bind the first
bromodomain of Brd4 with strong affinity, JQ1 and I-BET151,
have been developed (Fig. 2D) [57, 81, 82]. These drugs have
shown efficacy in cell culture and animal models, leading to
differentiation, cell cycle arrest, and apoptosis of MLL-FP
leukemia cells [57, 81]. Although the life span of leukemic
mice is extended by treatment with Brd4 inhibitors, the
animals do succumb to disease, suggesting that the inhibitor
needs to be improved or used in combination with other
therapies to treat MLL-FP leukemias.
The potential for targeting WT MLL to treat MLL-FP
leukemias
WT MLL is required for MLL-FP-mediated leukemogenesis [18].
Thus, blocking WT MLL function could hold therapeutic value
for patients with this disease. The development of specific
inhibitors of the WT MLL SET domain may inhibit WT MLL
functioning in MLL-FP-mediated leukemias. Additionally, the
TAD or PHD3 could potentially be targeted. However, the exact
mechanism by which WT MLL promotes MLL-FP-mediated
leukemogenesis is unknown. Also, while pharmacological
inhibition rarely completely inhibits the function of a protein,
complete ablation of WT MLL can cause defects in adult
hematopoiesis, suggesting that inhibition of WT MLL function
could lead to modest or even severe suppression of normal BM
[83–85].
Targeting menin, a central hub regulating WT MLL and
MLL-FPs to treat MLL-FP leukemias
Menin directly interacts with WT MLL and MLL-FPs, and is
necessary for directing these two critical components for leu-
kemogenesis to HOX genes, establishing menin as a hub in
this disease and a potential therapeutic target (Fig. 4) [9, 18,
60–63]. Further, menin directly interacts with LEDGF and C-
Myb [6, 7], strengthening the view that menin acts as a central
‘‘hub’’ for these various complexes and is suitable for thera-
peutic targeting (Fig. 4). Therefore, inhibiting menin may treat
MLL-FP leukemias more effectively. In addition, inhibition of
menin may be less toxic, as menin depletion causes a func-
tional defect in LT-HSCs, but does not affect steady-state
hematopoiesis [14].
Crystal structures of menin complexes have revealed
promising drug targets for the therapy of MLL-FP-mediated
leukemia through menin inhibition (Fig. 3). The hydrophobic
menin pocket that binds MLLMBM is specifically shaped for the
phenyl ring of phenylalanine. Substitution of the phenyl ring
with an imidazole ring of histidine or a hydroxyphenyl ring of
tyrosine abolishes menin–MLL interaction [62]. Thus, inhi-
bition of the menin–MLL interaction could be achieved with
small aromatic compounds.
In addition, two phenol rings of MLLLBM bind the hydro-
phobic pocket of the LEDGFIBD (Fig. 3D). This interaction
is another potential target for blocking the formation of the
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menin–MLL–LEDGF complex. A potent inhibitor of the menin/
MLL-N interaction has recently been developed. This thieno-
pyromidine class compound, termed MI-2, inhibits the inter-
action between MLL-FPs and menin, and blocks MLL-FP
induced transformation [60], providing a proof of principle
for targeting menin in MLL-FP leukemias.
Conclusions and outlook
Recently, significant progress has been made in understand-
ing the mechanisms by which the menin/WT MLL/MLL-FP
hub upregulates a subset of MLL target genes and drives
leukemogenesis. In addition to MLL target gene upregulation,
MLL-FPs work in concert with various signaling pathways
to promote leukemia. Menin acts as a central hub through
its role in recruiting WT MLL and MLL-FPs to target genes.
Menin also links C-Myb/LEDGF to the MLL N-terminus, further
highlighting menin’s central role in this disease. A more
detailed understanding of the molecular mechanism of
menin/WT MLL/MLL-FP-mediated upregulation of target
genes and potential interactions with crucial signaling
pathways may provide additional therapeutic targets for this
disease.
Increasing knowledge about the mechanism of MLL-FP-
mediated leukemogenesis has led to the possibility of treating
this disease with targeted therapeutics. MLL-FP function can
be suppressed by inhibition of Dot1L catalytic activity [36], and
MLL-FP cells are also sensitive to the BET bromodomain
inhibitors JQ1 and I-BET151 [57, 81]. JQ1 and I-BET151 are
the first in a new class of small molecules inhibiting readers
of epigenetic marks. The development of additional drugs in
this class could be used to inhibit other reader proteins that
may be important for MLL-FP-mediated leukemogenesis
(Fig. 2). Inhibition of the menin/MLL-N interaction with the
small molecule MI-2 is effective in blocking MLL-FP-induced
transformation [60], providing proof of principle for targeting
this interaction to treat patients with this disease. Inhibiting
the menin/MLL/MLL-FP hub in combination with targeted
therapies based on pathways interacting with the menin
hub or conventional chemotherapeutic agents will likely lead
to a more favorable prognosis for MLL-FP leukemia patients in
the future.
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